Alimera Sciences (NASDAQ:ALIM) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a hold rating to a buy rating in a research report sent to investors on Monday.

Separately, Maxim Group began coverage on Alimera Sciences in a research report on Monday, March 25th. They issued a buy rating and a $10.00 target price on the stock.

Alimera Sciences Stock Up 6.0 %

Shares of Alimera Sciences stock opened at $3.54 on Monday. The business’s 50 day simple moving average is $3.71 and its 200 day simple moving average is $3.62. Alimera Sciences has a 52-week low of $1.56 and a 52-week high of $4.38. The firm has a market cap of $185.32 million, a PE ratio of -1.64 and a beta of 1.18. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The firm had revenue of $26.31 million during the quarter, compared to analyst estimates of $25.10 million. During the same period in the prior year, the business posted ($0.54) EPS. On average, analysts predict that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AIGH Capital Management LLC bought a new position in Alimera Sciences in the third quarter valued at approximately $7,355,000. Stonepine Capital Management LLC bought a new position in Alimera Sciences in the third quarter valued at approximately $12,349,000. Finally, Worth Venture Partners LLC bought a new position in Alimera Sciences in the third quarter valued at approximately $1,840,000. 99.83% of the stock is currently owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).